Skip to navigation menu Skip to content
Illustration of a calendarIllustration of a document pageIllustration of a heart over a handIllustration of an envelopeIllustration of the letter i inside a circleIllustration of a map markerIllustration of a caduceusIllustration of a user with a plus signIllustration of a telephoneIllustration of a question mark inside a circleIllustration of a video cameraDocument with a PDF label
Current Research Studies

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) with Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (WAVE T1D)

WAVE T1D

  • Phase: I/II

What is the goal of the study?

This study is being done in people with newly diagnosed Type 1 Diabetes (T1D). We want to see if using a treatment called Anti-thymocyte Globulin (ATG), followed by either Adalimumab or Verapamil, can help people keep making insulin for a longer time which may also help to control blood glucose.

Who can participate in the study?

- recent diagnosis of T1D (less than 6 months ago) - at least 9 years old and less than 21 years old - weigh more than 30 kg (66.1 lbs) - be fully vaccinated based on age guidelines, have received a flu vaccine if it is flu season - be willing to only use insulin and no other medicines to control blood sugar - able to swallow pills

Study Team: